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TCL1 is overexpressed in most cases of chronic lymphocytic leukaemias (CLLs). 2 Several studies have delineated the links existing between overexpression of TCL1 in CLL and some specific chromosomal abnormalities. Expression of TCL1 in CLL samples varied from complete absence to strong expression, and was dependent of the immunophenotypic and molecular CLL subgroups. 2 Cases that strongly expressed TCL1 were more frequently found in cohorts having either (i) higher expression levels of ZAP70, (ii) unmutated IgVH genes and/or (iii) loss or monosomy of the 11q22/ATM locus. A correlation between the high expression of TCL1 and 11q deletion was also described by Pekarsky et al., 3 who showed that a high expression of TCL1 was frequently observed, whereas a low expression was very rare in aggressive CLLs with 11q deletions (11qÀ) (24 out of 32 and 1 case out of 32, respectively). Taken together, these results suggest that the overexpression of TCL1 in CLL can be linked with a deletion of 11q. The mechanisms underlying TCL1 overexpression in B-cell pathologies, especially in 11qÀ CLL, are poorly understood.
MicroRNAs (miRNAs) are key regulators of protein expression in many situations. These highly conserved 21-23-mer RNAs regulate the expression of genes by binding to the 3 0 -untranslated regions (3 0 -UTR) of specific mRNAs and block translation of the target proteins and/or shorten half-lives of the transcripts.
Two miRNAs (that is, miR-29 and miR-181) are downregulated in aggressive 11qÀ CLL and can regulate TCL1 protein expression. 3 By itself, this finding is not sufficient to explain why 11qÀ CLLs overexpress TCL1, as miR-29 and miR-181 genes are located on other chromosomal regions. We hypothesized that negative regulator(s) of TCL1 expression, located in the 11q chromosomal region, might be deleted in aggressive 11qÀ CLL, and that these negative regulators could correspond to miRNAs.
Single-nucleotide polymorphism-chip analysis allows singlenucleotide polymorphism genotyping as well as detection of copy number changes and acquired uniparental disomies. We analysed 13 CLL samples carrying a deletion at 11q22 previously detected by fluorescence in situ hybridization with an ATM probe. Single-nucleotide polymorphism-chip analysis using Affymetrix GeneChip Human Mapping 250K Nsp singlenucleotide polymorphism arrays detected 11q hemizygous deletions in all of these ATM À/ þ samples (copy number ¼ 1). Figure 1 delineates precisely the extent of the deletion in the 13 samples.
We found that the genomic region encoding the miR-34b and miR-34c miRNAs was deleted in 12 of the 13 cases. This miR-34b/c genomic region was also deleted in all of the six previous 11qÀ CLLs that we had previously described. 4 Interestingly, one sample described by Lehmann et al. 4 had two small deletions in 11q22 and 11q23.1. The first deletion (11q22) included the ATM gene. The second deletion (11q23.1) contained six genes including BTG4, which is indeed antisense to the gene coding for the miRNAs miR-34b and miR-34c. None of the other miRNAs located in the same region (that is, miR-1261, miR-1304, miR-548l, miR-100 and miR-125b-1) was deleted more than five times.
The miRNAs of the miR-34 family (namely miR-34a, miR-34b and miR-34c) are important components of the p53 network. 5 Their expression is induced by p53 and they mediate some of the pro-apoptotic effects of this key cellular factor. It is worth noting that an ambiguity in nomenclature exists for the miR-34s in miRBase, the reference database of all known miRNAs (http://microrna.sanger.ac.uk/). MiRBase (version 13) describes for the human miR-34a and miR-34c two homologous sequences, derived from the 5 0 -arm (called the '5p' arm) of their respective pre-miRNAs. On the other hand, the sequence for miR-34b stored in miRBase corresponds to the 3 0 ('3p') arm of pre-miR-34b. This sequence is indeed very different from miR-34a and miR-34c. The sequence called miR-34bn in miRBase derives from the 5p arm of the pre-miR-34b. We observed in human cell lines that miR-34bn is expressed (unpublished observations), which means that miR-34bn is a mature miRNA produced from the pre-miR-34b. In Rattus norvegicus and in Mus musculus, the mature miRNAs derived from the 5p arm of the precursors are called miR-34b and miR34b-5p, respectively. For the sake of clarity, we use in the rest of the manuscript the nomenclature: miR-34b-5p.
By looking at sequences showing exact matches with nucleotides (nts) 2-7 of the three members of the miR-34 family (as implemented by the MicroCible function available at http://www.microarray.fr/microRNA), one can predict that TCL1A is targeted by miR-34b-5p at four different positions but not by miR-34a nor by miR-34c. Three of these are contained within a 28-nt sequence repeated three times in the 3 0 -UTR ( Figure 2b ). A fragment of TCL1A 3 0 -UTR containing the 28-nt repeats (nts 437-589 from the 3 0 -UTR of transcript NM_021966) was inserted into a psiCheck2 plasmid (Promega, Charbonnières-les-Bains, France) downstream to a luciferase coding sequence. HEK293T cells were co-transfected with this plasmid and with each of the three miR-34s or with a negative control. MiR-34b-5p, but not miR-34a or miR-34c, was able to downregulate the luciferase activity, suggesting that TCL1A is indeed targeted by this miRNA (N ¼ 3 independent experiments, Figure 2d ).
Having almost identical sequences at their 5 0 extremities, and being identically induced by p53 5 , one could argue that miR-34a and miR-34b/c are functionally redundant, and thus that the deletion of the miR-34b/c gene in 11qÀ CLL could be compensated by the expression of miR-34a. The inhibitory role that miR-34b-5p specifically exerts on TCL1 expression is an argument against this hypothesis. To reinforce the concept that some of the targets of miR-34b-5p are not modulated by miR34a/c, we noticed that miR-34b-5p differs from mir-34a and miR-34c by one additional base at its 5 0 extremity (Figure 2a ). This is of potential importance, as in miRNAs, the 'seed' sequence (corresponding to nts 2-7) has a crucial role for the interaction with the mRNA targets. This one-base shift is therefore expected to change significantly the list of targets of miR-34b-5p, which should differ to some extent from the list of targets for miR-34a and miR-34c. This hypothesis was confirmed after looking whether the list of targets of miR-34b-5p differed significantly from the lists of targets of miR-34a and miR-34c. To that end, we established the expression profiles of HeLa cells transfected with miR-34a, miR-34b-5p, miR-34c or a negative control (miR-Neg1) using pan-genomic microarrays. Figure 3a shows a heatmap of the downregulated mRNAs where transcripts downregulated in miR-34a-and miR-34c-transfected cells are grouped together, in agreement with their identical seed sequences. A distinct expression profile was observed for the cells transfected with miR-34b-5p (Figure 3a) , revealing that the specific effects of miR-34b-5p observed for TCL1 can also be observed with other targets.
Gene expression data derived from HeLa cells transfected with the three distinct forms of miR-34 were then analysed with Sylamer, 6 to identify short nucleotide sequences enriched in the 3 0 -UTRs of the inhibited transcripts. When applied to cells transfected with miR-34a, the most frequent 6-nt motif found in the 1000 most downregulated transcripts was ACTGCC (Figure 3b ). This corresponds exactly to the complementary sequence of the seed (nts 2-7; GGCAGU) of miR-34a, suggesting that the inhibition observed in the transfected cells was largely due to direct effects of miR-34a. This is in line with the major functional importance of the nts 2-7 of the miRNA sequence in the formation of a complex with its targets.
A similar analysis was made for cells transfected with miR34b-5p and mir-34c, for which the most over-represented motifs were CTGCCT and ACTGCC, respectively. These two sequences also corresponded to the seed sequences of the transfected miRNAs (AGGCAG for miR-34b-5p; GGCAGU for miR-34c). This strengthens the idea that miR-34b-5p has, to some extent, specific targets due to the additional nt at its 5 0 -end, and thus that the deletion of the gene coding for this miRNA could not be functionally compensated by a normal expression of miR-34a. A deletion of the long arm of chromosome 11 is found in 10-20% of CLL patients and identifies a group with a poor outcome. In this report, we show that the genomic region encoding the miRNAs miR-34b and miR-34c is deleted in 12 of 13 11qÀ CLL cases. Taken together with six additional 11qÀ CLL cases that we have previously described, 4 the miR-34b/miR-34c genomic region was deleted in 18 of 19 11qÀ CLL samples. The frequent occurrence of miR-34b/miR34c deletion in 11qÀ CLLs, and the known functions of miR-34s in the control of cell proliferation and survival, allows us to Letters to the Editor hypothesize that loss of miR-34b/miR-34c might have a role in the phenotype associated with the aggressive 11qÀ CLL.
We also showed that the oncogene TCL1 is targeted by miR34b-5p. This might contribute to the overexpression of TCL1 characterizing 11qÀ CLLs, even if this interaction remains to be confirmed directly in CLL cells. It is also quite likely that additional targets of miR-34b play a role in the mechanism.
One of the 19 cases did not show any deletion in the miR34bc locus. One explanation can be proposed, based on previous works performed in SIHN-011B, a head and neck cancer cell line, 7 where the pre-miR-34b/c promoter was shown to be hypermethylated. This led to a downregulation of mature miR-34b and miR-34c, and to an overexpression of CDK6, C-MYC or E2F3, that is several target genes of miR-34b and/or miR-34c associated to 'cell cycle'. 7 It was shown by the same authors that the expression of miR-34b and miR-34c was restored by the DNA-demethylating agent 5-aza-2 0 -deoxycytidine, highlighting a possible role of miR-34b/c in the therapeutic effects of the epigenetic treatments. Alteration in the level of methylation of the pre-miR-34b/c promoter could be an explanation for the case where no deletion of the miR-34b/c region was detected.
The loss of chromosomal band 17p13, containing the gene coding for p53, is another common genomic aberration that identifies adverse clinical outcome in CLL. miR-34 family members are direct p53 targets, raising the possibility that miR-34 synthesis was impaired in 17pÀ CLLs. Indeed, Zenz et al. 8 showed that miR-34a was upregulated in CLL cells after DNA damage in the presence of a functional p53 but not in cases with 17p deletion. Taken together, accumulating evidence focuses attention on the downregulation of the miR-34s in the pathogenesis of aggressive CLLs.
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The authors declare no conflict of interest. 0 -UTR. Grey boxes delineate the three identical 28-nt repeats, each harbouring near its 3 0 -end the sequence CUGCCU complementary to the seed of miR-34b-5p. The underlined nucleotides delineate the DNA fragment cloned into psiCheck2. (c) Sequence alignment of miR-34b-5p with one of the three repeated putative hybridization sites. The free energy of this hybridization is À21.9 kcal/ mol. (d) miR-34b-5p regulation of TCL1 expression in the luciferase assay. HEK293 cells were co-transfected with negative control microRNA (miR-NEG) or one of the miR-34s as indicated and a psiCheck2 plasmid containing the three 28-nt repeats of the 3 0 -UTR of TCL1A. Histograms represent mean ± s.e.m. of renilla luciferase activity normalized to firefly luciferase activity. Experiments were performed in quadruplicate. The statistical significance between luciferase activities measured in miR-34b-5p-and miR-NEG-transfected cells is indicated by an asterisk. P-value was determined with a Wilcoxon two-sample test (Po0.028). 0 -UTR of the 1000 most downregulated transcripts. The written sequences correspond to the most statistically enriched motifs. They correspond to the hybridization sequence for the seed of the transfected microRNA (see Figure 2a) . In the case of miR-34b-5p, the second most statistically represented motif (Àlog 10 (P-value ¼ 4.7)) is ACTGCC, corresponding to the nts 3-9 of miR-34b-5p. The experiment was archived at Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) under the accession number GSE15957. The biology of bone destruction in multiple myeloma (MM) includes an increased activity of osteoclasts, which is accompanied by a reduction in osteoblast function leading to a high resorptive phase and subsequent bone loss. Macrophage inflammatory protein-1a (MIP-1a) is a low-molecular-weight chemokine that belongs to the regulated upon activation, normal T-cellexpressed and presumably secreted (RANTES) family. MIP-1a is produced by myeloma cells and enhances osteoclast activity in the myeloma microenvironment, acting on differentiated osteoclasts in a dose-dependent manner. 1 Earlier studies have shown that MIP-1a levels are elevated in the bone marrow plasma and the serum of patients with MM, whereas serum MIP-1a and the gene expression of MIP-1a correlate with the presence of lytic lesions in MM.
2,3 MIP-1a is a chemoattractant for monocytes and recently it was shown that monocytes may give rise to vascular endothelium. 4 Thus, our hypothesis was that myeloma cells express MIP-1a and other chemoattractants for monocytes and macrophages, and this expression correlated with both increased bone resorption (as osteoclasts are originated from a macrophage lineage precursor cell) and increased angiogenesis. The aim of our study was to evaluate the role of MIP-1a immunoexpression on trephine biopsies in the development of myeloma bone disease and examine possible correlations between MIP-1a expression and clinical data, including prognostic factors of MM and angiogenesis.
Patients with newly diagnosed MM having a bone marrow trephine biopsy before any kind of anti-myeloma therapy administration, including bisphosphonates and steroids, were eligible for participating in the study. Evidence of bone involvement at the time of diagnosis was documented using plain radiography. A grading of bone morbidity into three groups according to the radiographic evaluation of the skeleton was made. Group A included patients with no lytic lesions, group B included patients with osteolytic lesions in 1-3 areas and group C included patients with lytic lesions in more than three areas and/or a pathological fracture due to MM. The study was conducted after obtaining an approval from the Ethics Committee/Institutional Review Board and an informed consent was obtained from all patients before any intervention.
Bone marrow trephine was paraffin embedded and decalcified with a low pH EDTA buffer (EDTA-HCL). Immunochemistry staining was performed in an automatic instrument (XT Benchmark, Ventana, Tucson, AZ, USA) using an anti-MIP-1a monoclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and the dilution was 1:20. The immunoreactivity of MIP-1a was examined on the basis of positive plasma cells (PCs) with the following cutoff values: o20% positive PCs (negative group, group I), 20-50% positive PCs (intermediate expression group, group II) and 450% positive PCs (high expression group, group III). MIP-1a expression was also evaluated in 10 patients with monoclonal gammopathy of undetermined significance (MGUS). An immunochemical identification of microvascular endothelial cells was also performed in the above bone marrow specimens with a human monoclonal antibody against CD34 (DAKO A/S, Glostrup, Denmark) and VEGF (DAKO A/S, Glostrup, Denmark) by two experienced pathologists at Â 400 magnification, as described earlier. 5 In each biopsy sample, microvessels were counted in at least three independent hot spots per section and the microvessel density (MVD) of a bone marrow specimen was calculated as the mean value of all independent readings and recorded as the number of microvessels per Â 400 field. When the microvessel count was 1-2, angiogenesis was characterized to be of low grade, whereas intermediate-grade angiogenesis was defined by the presence of a microvessel count of 3-6 and high-grade angiogenesis by the presence of a
